Prevalence and risk factors of myocardial remodeling in hemodialysis patients myocardial remodeling in hemodialysis patients

Renal Failure

Volumn 31, Issue 8, 2009, Pages 662-667

  Dimitrijevic, Zorica ^a   Cvetkovic, Tatjana ^a   Stojanovic, Miomir ^a   Paunovic, Karolina ^a   Djordjevic, Vidojko ^a  

^a Clinical Center Nis Serbia   (Serbia)

Author keywords

Geometric remodeling; Hemodialysis; Inferior vena cava; Left ventricular hypertrophy

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART VENTRICLE REMODELING; HEMODIALYSIS; HUMAN; INFERIOR CAVA VEIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; AGED; COMORBIDITY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RISK FACTORS; VENTRICULAR REMODELING;

EID: 71049126209     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903100705     Document Type: Article

References (43)

1. Morton CC. U.S. dialysis survival strategy. Ann Intern Med. 1998;128:514-516.
2. Raine AEG, Margreiter R, Brunner FP. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992; 7(Suppl. 2);7-35. (Pubitemid 23049872)
3. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
4. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12: 1079-1084.
5. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
6. Ghali JK, Liao Y, Simmons B. Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:826-831.
7. Levy D, Garrison RJ, Savadge DD, Kannel WB, Castelli WP. Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;332:1561-1566.
8. Bolognese L, Dellavessa P, Rossi L. Sarasso G, Bongo AS, Scianaro MC. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vesel coronary artery disease. Am J Cardiol. 1994;73:1-5.
9. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int. 1987;31:973-980.
10. Foley RN, Parfrey PS, Harnett JD. Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024-2031.
11. Koren MJ, Devereux RB, Casale PN. Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertentoin. Ann Intern Med. 1991;114:342-352.
12. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879-884.
13. Shigematsu Y. Clinical evidence for association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens. 1995;13:155-160.
14. Verdecchia P, Giuseppe S, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic significance of concentric remodelling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25(4): 871-878.
15. Parfrey PS. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000;15(Suppl. 5):58-68.
16. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertention. J Am Coll Cardiol. 1992;19:1550-1558.
17. Foley RN, Parfrey PS, Harnett JD. Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in end-stage renal disease: Prevalence, associations and prognosis. Kidney Int. 1995;47:186-192.
18. London GM, Fabiani F. Left ventricular dysfunction in endstage renal disease: Echocardiographic insights. In Parfrey PS, Harnett JD (eds.). Cardiac dysfunction in chronic uremia. Boston: Kluwer; 1992:117-138.
19. Levin A, Thompson CR, Ethier J. Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
20. Ha SK, Park HS, Kim SU, Park SH, Park CH, Lee HY, Han DS, Kim KW, et al. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. J Korean Med Sci. 1998;13:488-494.
21. Straumann E, Bertel O, Meyer B. Weiss P, Misteli M, Blumberg A, Jenzer H. Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. Clin Cardiol. 1998;21:672-678.
22. Greaves SC, Sharpe DN. Cardiovascular disease in patients with end-stage renal failure. Aust NZ J Med. 1992;22:153-158.
23. Greaves C, Gamble GD, Collins JE, Whalley GA, Sharpe DN. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis. 1994;24:768-776.
24. Thuraisingham RC, Tucker B, Lipkin GW. Left ventricular hypertrophy in early renal failure. Nephrol Dial Transplant. 1994;7:859-860.
25. London G, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Adv Renal Replace Ther. 1997;4:194-211.
26. Levin A, Singer J, Thompson CR, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354.
27. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
28. Cheriex EC, Leunissen KML, Janssen JHA, Mooy JMV, Van Hooff JP. Echocardiography of the inferior vena cava is a simple and reliable tool for estimation of dry weight in hemodialysis patients. Nephrol Dial Transplant. 1989;4: 563-568.
29. De Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol. 2003;14:2421-2427.
30. Devereux R, de Simone G, Ganau A Koren MJ, Mensah GA, Roman MJ. Left ventricular hypertrophy and hypertension. Clin Exper Hypertens. 1993;15:1025-1032.
31. Klingbeil A, Schmeider R. Not all left ventricular hypertrophy is created equal. Nephrol Dial Transplant. 1999;14: 2803-2805.
32. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40:728-736.
33. Zoccali C, Mallamaci F, Tripepi G, CREED Investigators. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. J Hypertens. 1999;17:1751-1758.
34. Rao M, Pereira BJG. Optimal management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68:1432-1438.
35. London GM, Marchais SJ, Guérin AP, Fabiani F, Métivier F. Cardiovascular function in hemodialysis patients. Adv Nephrol. 1991;20:249-273.
36. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11: 1277-1285.
37. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884-890.
38. Lester LA, Sodt PC, Hutcheon N, Arcilla RA. Cardiac abnormalities in children with sickle cell anemia. Chest. 1990;98:1169-1174.
39. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
40. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642-1644.
41. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves cardiac function in chronic hemodialysis patients. Am J Nephrol. 1991;11: 54-60.
42. Foley RN, Parfrey PS, Morgan J Barré PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-1335.
43. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.